Beyer Russell P 4
4 · SAB Biotherapeutics, Inc. · Filed Nov 16, 2021
Insider Transaction Report
Form 4
Beyer Russell P
Chief Financial Officer
Transactions
- Award
Common Stock
2021-09-29$10.08/sh+10$101→ 15 total(indirect: By daughter) - Sale
Common Stock
2021-10-26$7.90/sh−278$2,196→ 0 total(indirect: By Spouse) - Award
Common Stock
2021-09-28$10.07/sh+5$50→ 5 total(indirect: By daughter) - Award
Common Stock
2021-10-25$7.78/sh+129$1,004→ 278 total(indirect: By Spouse) - Award
Common Stock
2021-10-18$10.10/sh+2,475$24,998→ 2,475 total - Award
Common Stock
2021-09-28$10.08/sh+149$1,502→ 149 total(indirect: By Spouse)
Footnotes (2)
- [F1]This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Issuer"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination.
- [F2]The sale of Issuer common stock by the reporting person's spouse reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 278 shares, with the purchase of 278 shares of Issuer's common stock as also reported herein. The reporting person has paid to Issuer, upon settlement of the sale, $15.48, representing the full amount of the profit realized in connection with the short-swing transaction.